Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Cardiovascular Diseases, Atherosclerosis, Myocardial Infarction
Interventions: Aspirin; Drug
Lead sponsor: Florida Atlantic University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Atlantis, Florida • Tamarac, Florida

Conditions: Endothelial Dysfunction
Interventions: Carbon Monoxide; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Peripheral Arterial Disease
Interventions: atorvastatin, ascorbic acid, Placebo; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Endothelial Cells, Exercise Tolerance
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Aging, Menopause
Interventions: MitoQ, Placebo, Aerobic exercise; Dietary Supplement · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 120 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Decompression Sickness, Endothelial Dysfunction, Neutrophil Activation, Venous Gas Emboli
Interventions: Aerobic running exercise; Other
Lead sponsor: University of Split; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coronary Artery Disease
Interventions: Grape seed extract and ascorbic acid; Dietary Supplement
Lead sponsor: Boston University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
Interventions: 17beta Estradiol, Transdermal placebo patch, Progesterone, Placebo Pill; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Augusta University; Other
Eligibility: 7 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Cardiovascular Diseases, Hypertension, Cognitive Decline, Diet, Healthy
Interventions: Peanut group; Dietary Supplement
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Glaucoma
Interventions: Sulcus tube placement, Anterior chamber (AC) tube placement; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: San Francisco, California • Walnut Creek, California • Miami, Florida + 4 more

Conditions: Healthy
Interventions: Cardiac MRI; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Endothelial Dysfunction
Interventions: Sapropterin Dihydrochloride, Sapropterin Dihydrochloride and Vitamin C; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Cornea Preservation Time, Endothelial Keratoplasty, Transplant Success, Endothelial Cell Density
Interventions: Cornea tissue transplant; Biological
Lead sponsor: Case Western Reserve University; Other
Eligibility: 30 Years to 90 Years
Enrollment: 1,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 40
States / cities: Beverly Hills, California • Los Angeles, California • San Diego, California + 35 more

Conditions: Aging, Endothelial Dysfunction, Arterial Stiffness
Interventions: Fisetin, Placebo; Dietary Supplement · Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 65 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: TVS, SHAM; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Atrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Endothelial Dysfunction
Interventions: Trimethaphan, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 2 Diabetes
Interventions: L-citrulline, Placebo; Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Coronary Artery Disease
Interventions: nitroglycerin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sarcoma
Interventions: Gemcitabine, Docetaxel and Bevacizumab; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 4
States / cities: Albuquerque, New Mexico • Santa Fe, New Mexico

Conditions: Endothelial Function, Rheumatoid Arthritis, Inflammation
Interventions: Rituxan; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Liver Cancer
Interventions: bevacizumab, dexamethasone, floxuridine, protein expression analysis, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging; Biological · Drug · Genetic + 2 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2024
U.S. locations: 2
States / cities: New York, New York

Conditions: Electronic Cigarette Use, Endothelial Dysfunction, Inflammation
Interventions: Placebo, Salsalate 750 MG Oral Tablet [DISALCID]; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 24 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa

Search by objective public record fields.

Aspirin Dose and Atherosclerosis in Patients With Heart Disease

Effects of Carbon Monoxide Breathing on Blood Vessel Function

Clinical Utility of Endothelial Dysfunction in PAD

Markers of Endothelial Function and Exercise CapaciTy in Patients With Left Ventricular Assist Devices (EFECT LVAD)

MitoQ and Exercise Effects on Vascular Health

Exercise and Repetitive Diving

Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function

Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women

Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF

Peanuts and Neurocognitive / Cardiovascular Health in Black Individuals

Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction

Cornea Preservation Time Study

Fisetin to Improve Vascular Function in Older Adults

Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure

The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation

Autonomic Nervous System and Nitric Oxide Interactions

The Effect of 4 Weeks of L-Citrulline Supplementation on Macro- and Microvascular Function in Type 2 Diabetes

Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease

Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma

Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use